mesoestetic® Pharma Group, a Spanish pharmaceutical laboratory and international benchmark in aesthetic medicine and cosmetics, has closed the 2025 fiscal year with a turnover of 86.8 million euros, consolidating a trajectory of sustained growth throughout its 40-year history and its role as a key player in a sector in full global expansion.
Excluding China, which remains the group's main individual market, mesoestetic® has registered a 20% growth, in line with a recurring organic evolution of between 15% and 20% annually. This dynamic confirms the solidity of the business model and the good evolution of all international markets, from a diversified strategy not dependent on a single country.
“The 2025 growth demonstrates the solidity of our model and our ability to grow sustainably without depending on a single market. The performance of the other geographies confirms that the international diversification strategy is yielding very positive results,” states Carles Font, Co-CEO & Chief Business Development Officer of mesoestetic® Pharma Group.
Balanced and diversified international growth
During 2025, mesoestetic® has continued to strengthen its balanced international growth strategy, with a focus on the consolidation of European markets, the boost of strategic markets in the American continent, such as the United States, Colombia, and Brazil, the sustained growth in proprietary markets and subsidiaries, and the development of the Chinese market from a non-dependent position and with a long-term vision.
The Spanish market reached in 2025 an approximate turnover of 10.45 million euros, which represents a growth close to 30% compared to the previous year, driven by the good performance of new launches in the medical channel, highlighting mesofiller® nexha and mesohyal®, and in the aesthetic channel such as skinretin xpert pack, as well as by the leadership of the depigmentation category.
Perspectives of growth and investment for 2026
By 2026, mesoestetic® Pharma Group expects to reach a turnover close to 91 million euros, maintaining its path of sustainable growth and its commitment to innovation, talent, and industrial independence.
In line with this strategy, the company will make an investment of 4 million euros between 2026 and 2027 earmarked for the incorporation of new production equipment, the improvement of logistics facilities and the implementation of advanced software for operations optimization.
During the first half of 2026, works on the mesoestetic® Campus will begin, an expansion of more than 21,000 m² with an investment of 42 million euros that will allow reinforcing the operational and scientific capacity of the company. The project will represent a significant boost for the local environment, consolidating the company's commitment to scientific development and the creation of more than 180 new qualified employment opportunities.
Scientific excellence and pharmaceutical development as drivers of growth
Innovation continues to be one of the strategic pillars of the group. In 2025, the company has reinvested 44% of its profits in I+D+i, driving the development of new solutions, the improvement of facilities, and the strengthening of integral control of the value chain, key to maintaining its positioning as a leading Spanish pharmaceutical laboratory internationally.
It also took a decisive step in its pharmaceutical evolution by becoming the first Spanish-capital company to obtain authorization for the commercialization of botulinum toxin. Along this same strategic line, mesoestetic® Pharma Group already has authorization for the manufacture of sterile medicines and hormone-based medicines, innovative solutions whose launch is scheduled for 2026.
The company foresees intense launch activity in all its other areas, with the expansion of the mesofiller® nexha range, the evolution of mesohyal® in biostimulation, new solutions based on exosomes, advances in epigenetics, the boost of the body category, and the consolidation of its professional device line The Fundamental Series.
Production, portfolio and solidity of the business model
In 2025, mesoestetic® has produced 6.7 million product units, strengthening its industrial capacity and the integral control of the value chain from its headquarters in Viladecans (Barcelona).
Among the best-selling products worldwide stand out cosmelan®, mesohyal®, mesoprotech® melan 130 pigment control, skinretin xpert pack, mesofiller® nexha and ha densimatrix, a reflection of a solid and diversified portfolio, with leadership in key areas such as depigmentation, anti-aging, and biostimulation.
The 50% of the business corresponds to the home channel, closely linked to professional prescription and the use of adjuvant solutions for medical and aesthetic treatments, which together represent 48% of the turnover. Medical-aesthetic devices (EBDs), after the launch of the new unit in 2023 and with a strong commitment for 2026 and 2027, currently represent the remaining 2%.
People, talent and commitment with the environment
mesoestetic® currently has a staff of 309 employees, from more than 20 nationalities, with 65% women and an average age of 36 years.
In 2025, the company created 16 new positions, internally promoted 15 people and had 34 interns, reinforcing its commitment to talent and professional development.
In parallel, mesoestetic® has maintained its commitment to the cultural and social environment, supporting initiatives such as the Palau de la Música Catalana, the Gran Teatre del Liceu and universities, institutes and talent programs, in line with its corporate responsibility policy linked to the promotion of young talent, culture and scientific research, consolidated in previous years. In this regard, the company plans to announce new collaborations linked to the territory in the coming months.